Work

Abstract 1727: Sequencing MEK inhibitor therapy after tovorafenib in BRAF fusion-driven cancers: Preclinical evidence of sustained tumor regression

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-1727

Authors: Samantha Perino, Yujin Wang, Shubhra Rastogi, Nur P. Damayanti, Karen E. Pollok, Sandya Govinda Raju, Mark W. Kieran, Samuel C. Blackman, Eleni Venetsanakos

Institutions: Day One Biopharmaceuticals (United States), Indiana University School of Medicine

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409631286

Cites:

Cited by:

Related to: 10